Selected article for: "causative agent and epithelial cell"
Author: Good, Steven S.; Westover, Jonna; Jung, Kie-Hoon; La Colla, Paolo; Collu, Gabriella; Moussa, Adel; Canard, Bruno; Sommadossi, Jean-Pierre
Title: AT-527 is a potent in vitro replication inhibitor of SARS-CoV-2, the virus responsible for the COVID-19 pandemic
  • Cord-id: tcncp3uf
  • Document date: 2020_8_11
    • ID: tcncp3uf
    Snippet: AT-527, an orally administered double prodrug of a guanosine nucleotide analog, has been shown previously to be highly efficacious and well tolerated in HCV-infected subjects. Herein we report the potent in vitro activity of AT-511, the free base form of AT-527, against several coronaviruses, including SARS-CoV-2, the causative agent of COVID-19. In normal human airway epithelial (HAE) cell preparations, the average concentration of AT-511 required to inhibit replication of SARS-CoV-2 by 90% (EC
    Document: AT-527, an orally administered double prodrug of a guanosine nucleotide analog, has been shown previously to be highly efficacious and well tolerated in HCV-infected subjects. Herein we report the potent in vitro activity of AT-511, the free base form of AT-527, against several coronaviruses, including SARS-CoV-2, the causative agent of COVID-19. In normal human airway epithelial (HAE) cell preparations, the average concentration of AT-511 required to inhibit replication of SARS-CoV-2 by 90% (EC90) was 0.5 µM, very similar to the EC90 for AT-511 against HCoV-229E, HCoV-OC43 and SARS-CoV in Huh-7 cells. No cytotoxicity was observed for AT-511 in any of the antiviral assays up to the highest concentration tested (100 µM). Surprisingly, AT-511 was 30-fold less active against MERS-CoV. This differential activity may provide a clue to the apparent unique mechanism of action of the guanosine triphosphate analog formed from AT-527.

    Search related documents:
    Co phrase search for related documents
    • active metabolite and adenosine nucleotide analog: 1
    • active metabolite and loading dose: 1, 2, 3, 4
    • active metabolite and long intracellular: 1
    • active site and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • active site and loading dose: 1
    • active site bind and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13
    • activity lack and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8
    • acute respiratory syndrome and adenosine nucleotide analog: 1, 2
    • acute respiratory syndrome and loading dose: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
    • acute respiratory syndrome and lung drug exposure: 1
    • loading dose and long intracellular: 1, 2
    • loading dose and lung drug exposure: 1